A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 572
Summary
- Conditions
- Bladder Cancer
- Colorectal Cancer
- Head and Neck Cancer
- Melanoma
- Non -Small Cell Lung Cancer
- Other Solid Cancers
- Renal Cancer
- Triple -Negative Breast Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03289962
- Collaborators
- BioNTech SE
- Investigators
- Study Director: Clinical Trials Hoffmann-La Roche